Goserelin to remain available to NZers

Published: Mon 19 Dec 2005 05:02 PM
Goserelin to remain available to NZers
People with prostate cancer and breast cancer will continue to have fully funded access to the hormonal treatment goserelin (Zoladex) following an agreement between Government drug-funding agency PHARMAC and pharmaceutical company AstraZeneca.
PHARMAC Medical Director Dr Peter Moodie says he is pleased that patients will continue to have access to the medicine following discussions between PHARMAC and AstraZeneca, while savings are maintained for taxpayers.
Both the one and three-month preparations of goserelin and leuprorelin will continue to be fully funded in the GnRH analogues therapeutic group.
Dr Moodie says the agreement with AstraZeneca is verbal, and subject to contracting and final approval.

Next in Lifestyle

Heritage Group Calls For Release Of Promised $250,000 Grant
By: Maia Hart - Local Democracy Reporter
Youth Want Tighter Vaping Controls
By: Asthma and Respiratory Foundation of New Zealand
Managing Muscle Soreness In A Post-Epidemic Gym Landscape
By: ExerciseNZ
Kiwi Student Helps Tongan Community Improve Drinking Water
By: University of Canterbury
Thousands Of Chocolate Lovers Gearing Up For Chocstock
By: Chocstock
The NZ Art Show Draws Record Crowds : A Cherished And Celebrated Event – 21 Years!
By: NZ Art Show
View as: DESKTOP | MOBILE © Scoop Media